The Department of Veterans Affairs in Washington, D.C., on June 22, 2026. (Photo by Ashley Murray/States Newsroom)
The Department of Veterans Affairs in Washington, D.C., on June 22, 2026. (Photo by Ashley Murray/States Newsroom) Credit: Ashley Murray/States Newsroom. States Newsroom photo republication terms

NOTE: This story mentions suicide. If you or a loved one needs help during a mental health crisis, call or text 988, or visit 988helpline.org. Help is available for veterans and nonveterans alike. 

WASHINGTON — Federal regulators could be on the cusp of approving psychedelic-assisted mental health treatment for veterans, but lawmakers asked tough questions Wednesday of Trump administration officials over whether the Department of Veterans Affairs can meet patients’ needs, and if federal law enforcement and health agencies are on the same page.

Just over 2 million veterans suffer with treatment-resistant depression, and approximately 180,000 of them would likely meet the criteria for treatment with psychedelic compounds, including MDMA, psilocybin, LSD, DMT and ibogaine, according to the Veterans Health Administration.

Members of the House Committee on Veterans Affairs Subcommittee on Health grilled officials for roughly two and a half hours during an afternoon hearing contemplating how the VA should implement the labor-intensive treatments if given the green light by the Food and Drug Administration.

Nearly 6,500 veterans died by suicide in 2024, according to the latest Veterans Affairs Suicide Prevention Annual Report, published in September.

“Something needs to change,” said subcommittee chair Rep. Mariannette Miller-Meeks, R-Iowa, who said despite prevention efforts, the numbers have remained “stubbornly stagnant.”

“When I came to Congress in 2021, I didn't think I'd be sitting here today advocating for these emerging breakthrough therapies, but in meeting with veterans from all walks of life, I have found the effectiveness of these treatments and am willing to advance it as potential hope,” said Miller-Meeks, who recently lost her bid for reelection.

Miller-Meeks, an Army veteran and ophthalmologist, cited randomized clinical trials for MDMA-assisted therapies that commenced this year at VA facilities in Rhode Island and Connecticut, both of which resulted from funding allocated in 2024. 

Miller-Meeks also praised President Donald Trump’s April executive order directing the FDA to work with other agencies, including the VA, the Drug Enforcement Administration, and the Department of Health and Human Services to remove barriers, like drug enforcement classification, that complicate testing the treatments.

The possibility of new treatments was met with optimism on both sides of the aisle.

The subcommittee’s ranking member Rep. Julia Brownley, D-Calif., said the clinical trials are “extremely welcome news and will change lives for the better.”

“At the same time, we must not lose sight of the fact that this treatment, much like the ones already in use today, will not be a panacea for everyone,” she said. “Even as VA works to build its capacity to provide access to these drugs, we must continue to maintain and strengthen the continuum of mental healthcare at VA.” 

Staff reductions present problem

During questioning Brownley expressed concern about VA’s ability to implement the new treatments in the wake of staff reductions under the Trump administration, if the FDA moves forward.

“Will VA be hiring additional workforce to meet the expected demand for these treatments and ensure existing workforce is not overtaxed if these treatments are approved in the next several months?” Brownley asked.  

Andrew Gradison, a Veterans Health Administration senior adviser who testified, acknowledged the treatments are “extremely labor intensive” and that along with preparation protocols, “dosing sessions alone can last six to eight hours.”

“We've conducted extensive analysis of the amount of staff time that goes into these treatments,” Gradison said. “We want to make sure that all of our initial implementation sites have the resources they need, not to have a detrimental impact on mental health access at large.”

Gradison told the panel that VA has identified 10 initial sites where treatment could occur, but would not publicly divulge every location. He said he would provide a list to all committee members within 30 days.

Rep. Herb Conaway, D-N.J., said “most of them are on the coast.”

“I see a lot in California. I see New Haven, Connecticut. I don't see any in the Southeast. New York is on this list as well. Do you believe that you have, even with those that you've established as possibly being ready, that you're sufficiently covering the country?” Conaway, a medical doctor, asked.

Dr. Ilse Wiechers, deputy assistant under secretary for health for patient care services with VA’s Veterans Health Administration, told Conaway,  “The reason you see the selected sites that you do is because those are the sites that we have evaluated to be the most likely to be successful in implementing this early on. 

“We are going to use that experience from those experienced sites,” she added.

Working with DEA

All the drugs under review remain categorized as Schedule I substances by federal law enforcement. 

Michigan Republican Rep. Jack Bergman, a retired U.S. Marine Corps lieutenant general, asked the expert panel, “What should VA be working out with DEA now, and where do you expect control substance requirements to cause the most delay?”

Marion Coe, director of clinical development and postmarketing surveillance at the healthcare industry consulting firm Pinney Associates, Inc., said the research involving these chemical compounds, particularly being able to legally store them, is a “complicated process.”

“VA and DEA ideally would work together to reduce these bureaucratic hurdles to make research easier,” she said. “This will all be made simpler after approval and rescheduling of these drugs.”